Submission Details
| 510(k) Number | K181871 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 12, 2018 |
| Decision Date | March 01, 2019 |
| Days to Decision | 232 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
K181871 is an FDA 510(k) clearance for the EliA Celikey IgG Immunoassay; EliA GliadinDP IgA Immunoassay; EliA GliadinDP IgG Immunoassay, a Autoantibodies, Endomysial(tissue Transglutaminase) (Class II — Special Controls, product code MVM), submitted by Phadia AB (Uppsala, SE). The FDA issued a Cleared decision on March 1, 2019, 232 days after receiving the submission on July 12, 2018. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5660.
| 510(k) Number | K181871 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 12, 2018 |
| Decision Date | March 01, 2019 |
| Days to Decision | 232 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
| Product Code | MVM — Autoantibodies, Endomysial(tissue Transglutaminase) |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.5660 |